CYP1A2 - a novel genetic marker for early aromatase inhibitor response in the treatment of breast cancer patients
BACKGROUND: Endocrine resistance is a major obstacle to optimal treatment effect in breast cancer. Some genetic markers have been proposed to predict response to aromatase inhibitors (AIs) but the data is insufficient. The aim of the study was to find new genetic treatment predictive markers of AIs.METHODS: The ongoing population-based BC-blood study in Lund, Sweden includes women with primary bre